U.S. markets closed

NexPrise, Inc. (NXPS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.15000.0000 (0.00%)
At close: 3:25PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1500
Open0.1500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1500 - 0.1500
52 Week Range0.0001 - 0.1500
Volume17
Avg. Volume0
Market Cap480,000
Beta (5Y Monthly)-373.48
PE Ratio (TTM)N/A
EPS (TTM)-3.6380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Barrons.com

    Enzo Biochem and Tenneco See Activist Action

    Roumell Asset Management disclosed a large stake in molecular-diagnostics biotech Enzo Biochem and urged the company to accept the resignation of its CEO. Icahn Enterprises lowered its investment in auto-parts maker Tenneco.

  • DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021
    Business Wire

    DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021

    DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the 2021 Dermatology Summit virtual conference (the "Dermatology Summit") on Jan. 8, 2021. The Dermatology Summit uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.

  • DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry
    Business Wire

    DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry

    DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN has published the results of a large registry study finding that the evaluation of genomic atypia using DermTech’s Pigmented Lesion Assay (the "PLA") may be a superior approach to guide treatment decisions and manage pigmented lesions, when compared to visual assessment of pigmented lesions.